Wasilewska, Anna
Murray, Rose Ann
Sundberg, Aimee
Uddin, Sharif
Achenbach, Heinrich
Shavkin, Aleksey
Szabó, Tamás
Vergani, Andrea
Umeh, Obi
Article History
Received: 27 January 2021
Accepted: 24 January 2022
First Online: 2 March 2022
Declarations
:
: This study was approved by the Institutional Review Board at each center (see Additional Table InternalRef removed) and conducted in accordance with the International Council for Harmonisation of Good Clinical Practice and the Principles of the Declaration of Helsinki, and other applicable local ethical and legal requirements. Freely given informed consent was provided by all participants (and their parent or legal guardian for patients < 16 years old) during this study.
: Not applicable.
: RM, ASu and OU are employees of Shire Human Genetic Therapies Inc., a member of the Takeda group of companies, and stockholders of Takeda Pharmaceutical Company Limited. SU is an employee of Takeda Pharmaceuticals USA, Inc., and a stockholder of Takeda Pharmaceutical Company Limited. HA and AV were employees of Shire Human Genetic Therapies Inc., a member of the Takeda group of companies, and stockholders of Takeda Pharmaceutical Company Limited, at the time this study was conducted. AW, ASh and TS have no competing interests to declare.